Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-
related glycemic excursions through augmentation of insulin and inhibition of glucagon …

NAFLD is closely linked with hepatic insulin resistance. Accumulation of hepatic
diacylglycerol activates PKC-ε, impairing insulin receptor activation and insulin-stimulated …

Objective Obesity and its associated comorbidities represent a global health challenge with
a need for well-tolerated, effective, and mechanistically diverse pharmaceutical …

Obesity is a chronic disease with a continuously rising prevalence that currently affects more
than half a billion people worldwide. Energy balance and appetite are highly regulated via …

In the last two decades we have witnessed sizable progress in defining the role of
gastrointestinal signals in the control of glucose and energy homeostasis. Specifically, the …

Whilst the prevalence of obesity continues to increase at an alarming rate worldwide, the
personal and economic burden of obesity-related complications becomes ever more …

To achieve good metabolic control in diabetes and keep long term, a combination of
changes in lifestyle and pharmacological treatment is necessary. Achieving near-normal …

Aims/hypothesis The aim of this study was to assess the dose–response effects of the
subcutaneous glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide …

Abstract Purpose of Review Obesity is a global health crisis with detrimental effects on all
organ systems leading to worsening disease state and rising costs of care. Persons with …

Bariatric surgery for obesity has proved to be an extremely effective method of promoting
long-term weight reduction with additional beneficial metabolic effects, such as improved …